- Home
- BOLT vs CYCN Comparison
BOLT vs CYCN Comparison
Compare BOLT & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- CYCN
- Stock Information
- Founded
- BOLT 2015
- CYCN 2018
- Country
- BOLT United States
- CYCN United States
- Employees
- BOLT N/A
- CYCN N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- CYCN Health Care
- Exchange
- BOLT Nasdaq
- CYCN Nasdaq
- Market Cap
- BOLT 9.4M
- CYCN 8.0M
- IPO Year
- BOLT 2021
- CYCN N/A
- Fundamental
- Price
- BOLT $5.19
- CYCN $2.22
- Analyst Decision
- BOLT Buy
- CYCN
- Analyst Count
- BOLT 3
- CYCN 0
- Target Price
- BOLT $47.50
- CYCN N/A
- AVG Volume (30 Days)
- BOLT 14.4K
- CYCN 23.2K
- Earning Date
- BOLT 08-14-2025
- CYCN 08-05-2025
- Dividend Yield
- BOLT N/A
- CYCN N/A
- EPS Growth
- BOLT N/A
- CYCN N/A
- EPS
- BOLT N/A
- CYCN N/A
- Revenue
- BOLT $4,167,000.00
- CYCN $2,174,000.00
- Revenue This Year
- BOLT N/A
- CYCN N/A
- Revenue Next Year
- BOLT N/A
- CYCN N/A
- P/E Ratio
- BOLT N/A
- CYCN N/A
- Revenue Growth
- BOLT N/A
- CYCN N/A
- 52 Week Low
- BOLT $4.59
- CYCN $1.27
- 52 Week High
- BOLT $14.36
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- BOLT 46.64
- CYCN 38.54
- Support Level
- BOLT $4.81
- CYCN $2.45
- Resistance Level
- BOLT $5.28
- CYCN $2.59
- Average True Range (ATR)
- BOLT 0.26
- CYCN 0.23
- MACD
- BOLT 0.01
- CYCN 0.00
- Stochastic Oscillator
- BOLT 70.26
- CYCN 7.47
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.